PolyPeptide Group AG shareholders approved all board proposals at an extraordinary general meeting, electing a new board and removing longstanding transfer and voting restrictions, moves that will take effect only once Samsung Peptide AG's public tender offer settles. The decisions effectively hand control of the specialized peptide CDMO to a wholly owned subsidiary of Samsung Biologics Co., Ltd., marking a significant shift in ownership for a company that supplies peptide-based active pharmaceutical ingredients to pharma and biotech customers worldwide.
The new board will be led by John Chongbo Rim as chair, with Seungho Ryu, Cheol Woo Ryu, Mihyun Yang and Joonkyung Seong serving as members until the next annual general meeting. Cheol Woo Ryu and Seungho Ryu were also elected to the Remuneration and Nomination Committee. All elections are conditional on and effective as of the settlement of Samsung Peptide AG's offer for all publicly held registered shares of PolyPeptide, according to the announcement distributed via NEWMEDIAWIRE.
Shareholders additionally resolved to remove the transfer restrictions (Vinkulierung) and voting limitations (Stimmrechtsbeschränkungen) from PolyPeptide's articles of association, subject to the satisfaction or waiver of all offer conditions in the Offer Prospectus dated 31 August 2026, except for the condition in section B.7.1(e). The removal of these clauses is a structural prerequisite for the takeover: transfer restrictions and voting caps can otherwise impede an acquirer from fully exercising control over acquired shares. Their elimination signals that the transaction is expected to close and that Samsung intends to integrate PolyPeptide without the governance frictions typically associated with Swiss listed companies that retain such protections.
The implications extend beyond corporate governance. PolyPeptide operates six GMP-certified facilities across Europe, the U.S. and India and has significant exposure to metabolic diseases, including GLP-1 therapies, a fast-growing segment of the pharmaceutical market. A Samsung Biologics-controlled PolyPeptide would combine peptide manufacturing capacity with Samsung's broader biologics CDMO platform, potentially creating a more formidable competitor in the race to supply ingredients for obesity and diabetes drugs. For customers and investors, the board overhaul and the removal of voting limits reduce uncertainty about who will steer the company through that expansion.
The elections and article amendments remain contingent on the tender offer settlement, meaning the current board retains authority until the conditions are met. PolyPeptide's shares trade on SIX Swiss Exchange under the ticker PPGN, and the company dates back to 1952. Further details are available in the filing PolyPeptide_EGM Results 2026_ENG and the original release on www.newmediawire.com. The outcome gives Samsung Biologics a clear governance mandate while leaving the final step—settlement of the offer—as the decisive trigger for the new board and the amended articles to take effect.
